论文部分内容阅读
目的观察吡格列酮和二甲双胍治疗对2型糖尿病患者胰岛素抵抗(IR)的影响。方法 2型糖尿病患者50例一般治疗方案下,随机分为吡格列酮组及二甲双胍组,治疗疗程为12周。结果吡格列酮组和二甲双胍组在治疗后空腹和餐后C肽水平均较用药前有明显降低,IR稍有降低,β细胞功能明显改善,吡格列酮在降低餐后胰岛素、改善IR方面优于二甲双胍,两药治疗前后血游离脂肪酸水平未见统计学差异。结论吡格列酮和二甲双胍均有降低IR和改善β细胞功能,在降IR方面,吡格列酮优于二甲双胍。
Objective To observe the effects of pioglitazone and metformin on insulin resistance (IR) in type 2 diabetic patients. Methods Fifty patients with type 2 diabetes under general treatment were randomly divided into two groups: pioglitazone group and metformin group. The course of treatment was 12 weeks. Results Both fasting and postprandial C-peptide levels in pioglitazone group and metformin group were significantly lower than those before treatment, with a slight decrease in IR and a significant improvement in β-cell function. Pioglitazone was superior to metformin in reducing postprandial insulin and improving IR Before and after treatment of blood serum levels of free fatty acids showed no significant difference. Conclusion Both pioglitazone and metformin can reduce IR and improve β-cell function. Pioglitazone is superior to metformin in reducing IR.